Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers

v3.21.1
Revenues from Contracts and Significant Customers
 3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenues from Contracts and Significant Customers

18. Revenues from Contracts and Significant Customers

Disaggregation of Total Revenue

Product revenue is comprised of Journey’s seven marketed products: Targadox®, Luxamend®, Ceracade®, Exelderm®, Ximino®, Accutane® and Qbrexza®. Substantially all of the product revenue is recorded in the U.S. The Company’s collaboration revenue is from Cyprium’s agreement with Sentynl (see Note 3). The Company’s related party revenue is from Checkpoint’s collaboration with TGTX. The table below summarizes the Company’s revenue for the three months ending March 31, 2021 and 2020:

​

​

​

​

​

​

​

​

​

​

Three months ended March 31, 

​

    

2021

    

2020

Revenue

​

​

​

​

​

​

Product revenue, net

​

$

10,719

​

$

11,946

Collaboration revenue

​

​

800

​

​

—

Revenue – related party

​

 

68

​

 

972

Net revenue

​

$

11,587

​

$

12,918

​

Significant Customers

For the March 31, 2021, none of the Company’s dermatology products customers accounted for more than 10% of its total gross product revenue.

For the three months ended March 31, 2020, two of the Company’s dermatology products customers accounted for more than 10% of its total gross product revenue.

At March 31, 2021, none of the Company’s dermatology products customers accounted for more than 10% of its total accounts receivable balance.

At March 31, 2020, two of the Company’s dermatology products customers accounted for more than 10% of its total accounts balance in the amounts of $5.4 million and $2.5 million.